TABLE 3.

HPV-Type Prevalence Among ICC in Prevaccine and Postvaccine Studies From the CDC Sentinel Surveillance Study

		Prevaccine 1993–2005a			Postvaccine 2014–2015b
Age y	HPV Typec	No. of Patients	Unweighted %	95% CI	No. of Patients	Weighted %	95% CI	P d
Total			n = 772			n = 363		.32
	HPV 16, 18	512	66.3	62.9–69.6	262	69.3	62.9–75.1
	HPV 31, 33, 45, 52, 58	112	14.5	12.2–17.2	37	10.4	6.9–15.2
	Other oncogenic HPV	50	6.5	4.9–8.4	17	5.8	3.3–9.9
	Other HPV/HPV negative	98	12.7	10.5–15.2	47	14.5	10.3–20.0
19–34			n = 121			n = 96		.38
	HPV 16, 18	90	74.4	65.9–81.3	81	84.4	75.2–90.6
	HPV 31, 33, 45, 52, 58	19	15.7	10.3–23.2	6	5.7	2.5–12.2
	Other oncogenic HPV	6	5.0	2.3–10.4	3	3.5	1.1–10.6
	Other HPV/HPV negative	6	5.0	2.3–10.4	6	6.4	2.8–14.0
35–50			n = 309			n = 134		.46
	HPV 16, 18	231	74.8	69.6–79.3	101	75.0	65.3–82.8
	HPV 31, 33, 45, 52, 58	36	11.7	8.5–15.7	14	12.0	6.6–20.8
	Other oncogenic HPV	23	7.4	5.0–10.9	7	7.7	3.6–16.0
	Other HPV/HPV negative	19	6.1	4.0–9.4	12	5.3	2.6–10.4
50–94			n = 342			n = 133		.89
	HPV 16, 18	191	55.8	50.5–61.0	80	57.5	46.2–68.0
	HPV 31, 33, 45, 52, 58	57	16.7	13.1–21.0	17	11.2	6.0–20.0
	Other oncogenic HPV	21	6.1	4.1–9.2	7	5.3	2.1–12.8
	Other HPV/HPV negative	73	21.3	17.3–26.0	29	26.0	17.3–37.0

Abbreviations: CA, Los Angeles County, California; CDC, Centers for Disease Control; CIN3+, cervical intraepithelial neoplasia grade 3 and higher; FL, Florida; HI, Hawaii; HPV, human papillomavirus; IA, Iowa; ICC, invasive cervical cancer; KY, Kentucky; LA, Louisiana; MI, Michigan.

The data source was the CDC Cancer Registry Sentinel Surveillance System.

^aIncludes cases from cancer registries in FL, HI, IA, KY, CA, LA, and MI; unweighted frequencies.

^bIncludes cases from cancer registries in IA, KY, and LA. Frequencies weighted for age and race/ethnicity.

^dP values derived from generalized logit models adjusting for age and race/ethnicity.

^cOther oncogenic types include HPV 35, 39, 51, 56, 59, 66, and 68.